Neuregulin-3 Inhibitors

Neuregulin-3 inhibitors, as a chemical class, largely consist of compounds that target the ErbB family of receptors, given that Neuregulins, including NRG3, signal through these receptors. The primary focus of these compounds is the inhibition of the kinase activity of these receptors, particularly EGFR (ErbB1) and HER2 (ErbB2). In doing so, they can modulate the downstream signaling events initiated by Neuregulins. Gefitinib and Erlotinib, for instance, are known for their EGFR inhibition, affecting the phosphorylation and consequent activation of downstream molecules. Lapatinib, Afatinib, and Dacomitinib are broader in their action, with the capacity to target multiple ErbB receptors. This multi-target approach ensures a wider blockade of Neuregulin-induced signaling. While the primary focus of these compounds may not be the specific inhibition of NRG3, their mode of action indirectly affects the pathways in which NRG3 is involved. The utility of such compounds in research and other applications relies on their ability to modulate ErbB receptor signaling, offering an indirect method to study or influence Neuregulin-3 function.